Heart drug setbacks reshape cardiovascular R&D landscape

Two closely watched heart disease medicines failed in recent studies, prompting reassessment of therapeutic approaches in cardiovascular research. The setbacks raise uncertainty about the viability of certain drug targets and may shift industry investment toward alternative mechanisms. The full implications for ongoing trials and future development pipelines remain unclear.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works